The tumor mRNA expression levels of mammaglobin, a novel breast-specific and breast cancer-associated marker, were correlated with disease outcome in 280 patients with primary breast cancer.
As estrogen and antiestrogen treatment of estrogen-positive breast cancer cell lines does not modifySCGB2A2 expression we suggest that SCGB2A2 may be a new independent breast cancer prognostic marker.
TWIST1 (gene name: TWIST1), CK19 (gene name: KRT19), and hMAM (gene name: SCGB2A2) mRNA was quantitated in BM samples from 191 operable breast cancer patients by real-time reverse transcriptase polymerase chain reaction (RT-PCR).